BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 33160075)

  • 1. Dystrophin Gene-Editing Stability Is Dependent on Dystrophin Levels in Skeletal but Not Cardiac Muscles.
    Bengtsson NE; Tasfaout H; Hauschka SD; Chamberlain JS
    Mol Ther; 2021 Mar; 29(3):1070-1085. PubMed ID: 33160075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Vivo Genome Editing Restores Dystrophin Expression and Cardiac Function in Dystrophic Mice.
    El Refaey M; Xu L; Gao Y; Canan BD; Adesanya TMA; Warner SC; Akagi K; Symer DE; Mohler PJ; Ma J; Janssen PML; Han R
    Circ Res; 2017 Sep; 121(8):923-929. PubMed ID: 28790199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy.
    Bengtsson NE; Hall JK; Odom GL; Phelps MP; Andrus CR; Hawkins RD; Hauschka SD; Chamberlain JR; Chamberlain JS
    Nat Commun; 2017 Feb; 8():14454. PubMed ID: 28195574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Full-length dystrophin restoration via targeted exon integration by AAV-CRISPR in a humanized mouse model of Duchenne muscular dystrophy.
    Pickar-Oliver A; Gough V; Bohning JD; Liu S; Robinson-Hamm JN; Daniels H; Majoros WH; Devlin G; Asokan A; Gersbach CA
    Mol Ther; 2021 Nov; 29(11):3243-3257. PubMed ID: 34509668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AAV CRISPR editing rescues cardiac and muscle function for 18 months in dystrophic mice.
    Hakim CH; Wasala NB; Nelson CE; Wasala LP; Yue Y; Louderman JA; Lessa TB; Dai A; Zhang K; Jenkins GJ; Nance ME; Pan X; Kodippili K; Yang NN; Chen SJ; Gersbach CA; Duan D
    JCI Insight; 2018 Dec; 3(23):. PubMed ID: 30518686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Life-Long AAV-Mediated CRISPR Genome Editing in Dystrophic Heart Improves Cardiomyopathy without Causing Serious Lesions in mdx Mice.
    Xu L; Lau YS; Gao Y; Li H; Han R
    Mol Ther; 2019 Aug; 27(8):1407-1414. PubMed ID: 31129119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced CRISPR-Cas9 correction of Duchenne muscular dystrophy in mice by a self-complementary AAV delivery system.
    Zhang Y; Li H; Min YL; Sanchez-Ortiz E; Huang J; Mireault AA; Shelton JM; Kim J; Mammen PPA; Bassel-Duby R; Olson EN
    Sci Adv; 2020 Feb; 6(8):eaay6812. PubMed ID: 32128412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correction of Three Prominent Mutations in Mouse and Human Models of Duchenne Muscular Dystrophy by Single-Cut Genome Editing.
    Min YL; Chemello F; Li H; Rodriguez-Caycedo C; Sanchez-Ortiz E; Mireault AA; McAnally JR; Shelton JM; Zhang Y; Bassel-Duby R; Olson EN
    Mol Ther; 2020 Sep; 28(9):2044-2055. PubMed ID: 32892813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The gRNA Vector Level Determines the Outcome of Systemic AAV CRISPR Therapy for Duchenne Muscular Dystrophy.
    Wasala NB; Million ED; Watkins TB; Wasala LP; Han J; Yue Y; Lu B; Chen SJ; Hakim CH; Duan D
    Hum Gene Ther; 2022 May; 33(9-10):518-528. PubMed ID: 35350865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AAV9 Edits Muscle Stem Cells in Normal and Dystrophic Adult Mice.
    Nance ME; Shi R; Hakim CH; Wasala NB; Yue Y; Pan X; Zhang T; Robinson CA; Duan SX; Yao G; Yang NN; Chen SJ; Wagner KR; Gersbach CA; Duan D
    Mol Ther; 2019 Sep; 27(9):1568-1585. PubMed ID: 31327755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR-Cas9 corrects Duchenne muscular dystrophy exon 44 deletion mutations in mice and human cells.
    Min YL; Li H; Rodriguez-Caycedo C; Mireault AA; Huang J; Shelton JM; McAnally JR; Amoasii L; Mammen PPA; Bassel-Duby R; Olson EN
    Sci Adv; 2019 Mar; 5(3):eaav4324. PubMed ID: 30854433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing.
    Hanson B; Wood MJA; Roberts TC
    RNA Biol; 2021 Jul; 18(7):1048-1062. PubMed ID: 33472516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR-Cpf1 correction of muscular dystrophy mutations in human cardiomyocytes and mice.
    Zhang Y; Long C; Li H; McAnally JR; Baskin KK; Shelton JM; Bassel-Duby R; Olson EN
    Sci Adv; 2017 Apr; 3(4):e1602814. PubMed ID: 28439558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delivery of AAV2/9-microdystrophin genes incorporating helix 1 of the coiled-coil motif in the C-terminal domain of dystrophin improves muscle pathology and restores the level of α1-syntrophin and α-dystrobrevin in skeletal muscles of mdx mice.
    Koo T; Malerba A; Athanasopoulos T; Trollet C; Boldrin L; Ferry A; Popplewell L; Foster H; Foster K; Dickson G
    Hum Gene Ther; 2011 Nov; 22(11):1379-88. PubMed ID: 21453126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatic gene editing ameliorates skeletal and cardiac muscle failure in pig and human models of Duchenne muscular dystrophy.
    Moretti A; Fonteyne L; Giesert F; Hoppmann P; Meier AB; Bozoglu T; Baehr A; Schneider CM; Sinnecker D; Klett K; Fröhlich T; Rahman FA; Haufe T; Sun S; Jurisch V; Kessler B; Hinkel R; Dirschinger R; Martens E; Jilek C; Graf A; Krebs S; Santamaria G; Kurome M; Zakhartchenko V; Campbell B; Voelse K; Wolf A; Ziegler T; Reichert S; Lee S; Flenkenthaler F; Dorn T; Jeremias I; Blum H; Dendorfer A; Schnieke A; Krause S; Walter MC; Klymiuk N; Laugwitz KL; Wolf E; Wurst W; Kupatt C
    Nat Med; 2020 Feb; 26(2):207-214. PubMed ID: 31988462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AAV-Mediated Somatic Gene Editing for Cardiac and Skeletal Muscle in a Large Animal Model.
    Ziegler T; Bozoglu T; Kupatt C
    Methods Mol Biol; 2022; 2573():63-74. PubMed ID: 36040587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo non-invasive monitoring of dystrophin correction in a new Duchenne muscular dystrophy reporter mouse.
    Amoasii L; Li H; Zhang Y; Min YL; Sanchez-Ortiz E; Shelton JM; Long C; Mireault AA; Bhattacharyya S; McAnally JR; Bassel-Duby R; Olson EN
    Nat Commun; 2019 Oct; 10(1):4537. PubMed ID: 31586095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Creation of a Novel Humanized Dystrophic Mouse Model of Duchenne Muscular Dystrophy and Application of a CRISPR/Cas9 Gene Editing Therapy.
    Young CS; Mokhonova E; Quinonez M; Pyle AD; Spencer MJ
    J Neuromuscul Dis; 2017; 4(2):139-145. PubMed ID: 28505980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Applications of CRISPR/Cas for Duchenne Muscular Dystrophy.
    Wong TWY; Cohn RD
    Curr Gene Ther; 2017; 17(4):301-308. PubMed ID: 29173172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR-Cas9 Correction of Duchenne Muscular Dystrophy in Mice by a Self-Complementary AAV Delivery System.
    Zhang Y; Bassel-Duby R; Olson EN
    Methods Mol Biol; 2023; 2587():411-425. PubMed ID: 36401041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.